When should I recommend folate vs folic acid vs methylfolate?

How it works

MTHFR C677T polymorphism: TT homozygotes have around 20% residual enzyme function vs 66% in CC wild-type and 56% in CT; TT carriers run modestly higher homocysteine, particularly when folate intake is low. Standard folic acid supplementation effectively normalises homocysteine in TT carriers per peer-reviewed reviews (Genetic Polymorphisms and Folate Status, PMC5601299). Methylfolate is more bioavailable in some pharmacokinetic studies and is the form already circulating in plasma, but functional adequacy of folic acid in MTHFR carriers is established. Natural food folate bioavailability is roughly half of folic acid (Dietary Folate Equivalent factor 1.7).

Effective dose

Trial-supported doses for homocysteine lowering or cognitive support in MCI: VITACOG (Smith 2010 PMC2935890) 0.8 mg folic acid + 0.5 mg B12 + 20 mg B6 for 24 months; VITATOPS (PMID 20688574) 2 mg folic acid + 25 mg B6 + 500 mcg B12; HOPE-2 (Lonn 2006) 2.5 mg folic acid + 50 mg B6 + 1 mg B12. CSPPT (Huo 2015 JAMA) primary stroke prophylaxis in folate-naive Chinese hypertensives: 0.8 mg folic acid + enalapril vs enalapril alone, around 21% stroke reduction.

Forms compared

Folic acid recommended for: UK pregnancy supplementation per NICE NG201 (the form used in all major NTD prophylaxis trials including the UK MRC Vitamin Study 1991, the foundational evidence); general supplementation where indicated, aligning with UK fortification programme; UK BNF therapeutic uses (haemolytic anaemia, folate deficiency anaemia at 5 mg/day). Methylfolate (5-MTHF) reasonable for: documented poor folic acid response (rare), strong personal preference, existing methylfolate use being well-tolerated. Folinic acid: clinical only (oncology, methotrexate rescue), not a routine OTC supplement choice. Natural food folate: always the preferred dietary source where possible.

Timing

Methotrexate plus folic acid timing: take folic acid 24+ hours after methotrexate dose, not on the same day; same-day folic acid can compromise methotrexate efficacy. Some prescribers use 1 mg/day except on methotrexate day; both regimens are NICE-acceptable. Reassessment after repletion of established deficiency: 1-4 months depending on cause; check FBC and homocysteine if relevant.

Safety profile

Always check B12 alongside folate (serum or active B12; consider MMA in older adults or borderline cases). Where both deficient, address B12 first or in parallel with folate. NHS Eatwell guidance and the UK fortification programme do not raise this concern at population level (fortification doses are below the threshold for masking) but for individual high-dose supplementation it remains a hard rule. UMFA (unmetabolised folic acid): detectable at high folic acid intakes; SACN 2017 and EFSA 2023 (DOI 10.2903/j.efsa.2023.8353) both concluded evidence is insufficient to establish a causal relationship between folic acid intake and impaired cognitive function, colorectal cancer, or prostate cancer.

Special populations

Methotrexate users (rheumatology, oncology): folic acid 5 mg weekly is standard prophylaxis to reduce methotrexate toxicity (mucositis, nausea, hepatic effects, marrow suppression) without compromising disease-control efficacy per NICE NG100 and NG144. Coeliac and IBD users: folate deficiency common from malabsorption; supplementation often warranted. Long-term anticonvulsant users: phenytoin and valproate may lower folate; high-risk pregnancy category requires 5 mg/day folic acid.

Interactions

Critical caveat for phenytoin, phenobarbital, and primidone specifically: high-dose folic acid may reduce serum levels and clinical efficacy of these anticonvulsants, potentially increasing seizure risk; co-administration requires neurology awareness and seizure monitoring. Other anticonvulsants (lamotrigine, levetiracetam, carbamazepine, valproate, topiramate) do not have this interaction documented. Pemetrexed: folate-depleting; requires folic acid 350-1000 mcg/day plus B12 1000 mcg every 9 weeks per UK BNF; oncology-supervised. Form choice (folate vs folic acid vs methylfolate) does not materially change these interaction profiles; interaction is with the folate moiety regardless of form. Folate alone in B12 deficiency: the folate trap.

Guideline positions

UK Bread and Flour (Amendment) Regulations 2024 (laid 14 November 2024): mandate fortification of non-wholemeal wheat flour with folic acid at 0.25 mg per 100 g flour, legally required by 13 December 2026 (24-month transition). Wholemeal, gluten-free, and non-wheat flours excluded. Expected impact: around 20% reduction in NTD rates (around 200 cases/year averted per UK government estimate). UK pregnancy folic acid supplement advice (400 mcg/day pre-conception through 12 weeks) is unchanged by fortification. UK MRC Vitamin Study 1991 is the foundational NTD prophylaxis evidence (folic acid). Genetic Polymorphisms and Folate Status (PMC5601299) for the MTHFR carrier evidence base. Stabler 2013 NEJM (PMID 23301732) for the folate trap.

Practical framework

Causes of folate deficiency to investigate: alcohol use; malabsorption (coeliac, IBD, post-bariatric); increased requirement (pregnancy, lactation, haemolysis); medications (methotrexate, sulfasalazine, trimethoprim, anticonvulsants especially valproate and phenytoin, some antimalarials); restricted diets; long-term low-vegetable intake; rare hereditary folate transport disorders. UK practice uses standard folic acid in pregnancy regardless of MTHFR status; this is the evidence-based and cost-effective approach. This is a summary of published research, not personal health advice. Discuss any health or supplement decisions with a qualified healthcare professional, particularly during ongoing care, pregnancy, or with chronic conditions.

Common misconceptions

Claim: unmetabolised folic acid is dangerous at standard fortification or supplement doses. SACN 2017 and EFSA 2023 both concluded evidence is insufficient to establish a causal relationship between folic acid intake and impaired cognitive function, colorectal cancer, or prostate cancer; observational associations exist but causality is not established.

Claim: methylfolate causes anxiety or insomnia in COMT-variant carriers. This is a functional-framing claim not anchored in trial data.

Claim: starting folate when both B12 and folate are low is fine. The folate trap (haematological response masks while neurological damage progresses) is a core safety principle.

Claim: food folate alone is the safest approach. True that food folate carries no UMFA risk, but UK pregnancy guidance specifically requires the dose and reliability of folic acid supplementation; the NTD prophylaxis evidence base is built on folic acid.